Science

Biotech & Pharma Intelligence

Human-led · Source-checked

What happened in biotech, what the evidence supports, and what to watch next.

Daily or weekly · Open · Latest edition, free to read

Edition 052 · · 25 pages · About 37 min read

Erasca says 44% of 25 responded; it’s Phase 1

Read on screen

Bookmarks need a Mind Club sign-in. How sign-in works

In this edition

Read on screen About 37 min read

  1. 00 At a glance 4 min
  2. 01 Markets & outlook 3 min
  3. 02 Capital scorecard 2 min
  4. 02 Capital scorecard 2 min
  5. 03 Outlook 2 min
  6. 04 Five things to know 5 5 min
  7. 05 Five talking points 1 min
  8. 05B Claim Check 5 2 min
  9. 06 M&A, BD & licensing 2 min
  10. 07 Financing & capital markets 1 min
  11. 08 Clinical readouts 2 min
  12. 09 Novel biology & target watch 7 min
  13. 10 Policy & regulatory watch 2 min
  14. 11 Pattern recognition 1 min
  15. 12 What may be underestimated 1 min
  16. 13 Where this brief could be wrong 2 min
  17. 14 Verified Catalyst Calendar 3 min
  18. 14B Registry Watch 4 min
  19. 15 Public Calls Ledger 3 1 min
  20. 16 Ask Mind Club and corrections 1 min
  21. 17 Sources 1 min

On screen: the edition's own text and labels, as printed.

Browse editions

44 earlier editions.

Back issues are part of Biotech & Pharma for subscribers.

The latest edition is free to read. Subscribers can open every edition from the shelf link in any Mind Club email.

Join Mind Club (punitdhillon.com, opens in a new tab) Sign in

It’s complimentary.

Companion

Biotech Signal

Live · For Biotech & Pharma Intelligence

The live dashboard behind the brief.

  • Trial catalysts, graded A to F
  • Capital activity by area and deal type, including financings
  • Target Evidence Cards (Target Momentum)
  • Forecast records, and how each one resolved

Included with either Biotech & Pharma subscription option. Biotech Signal has its own sign-in for now.

Biotech & Pharma track record and corrections log (punitdhillon.com, opens in a new tab)